Cargando…

Participant and GP perspectives and experiences of screening for undiagnosed type 2 diabetes in community pharmacy during the Pharmacy Diabetes Screening Trial

BACKGROUND: The Pharmacy Diabetes Screening Trial (PDST) evaluated three approaches to screening for undiagnosed type 2 diabetes mellitus (T2DM) in community pharmacy: (1) paper-based risk assessment (AUSDRISK) alone; and AUSDRISK followed by a point of care test if AUSDRISK ≥ 12; with either (2) Hb...

Descripción completa

Detalles Bibliográficos
Autores principales: Krass, Ines, Twigg, Michael J., Mitchell, Bernadette, Wilson, Frances, Mohebbi, Mohammadreza, Trinder, Peta, Shih, Sophy T. F., Carter, Rob, Versace, Vincent L., McNamara, Kevin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10693079/
https://www.ncbi.nlm.nih.gov/pubmed/38041094
http://dx.doi.org/10.1186/s12913-023-10269-1
_version_ 1785153080085446656
author Krass, Ines
Twigg, Michael J.
Mitchell, Bernadette
Wilson, Frances
Mohebbi, Mohammadreza
Trinder, Peta
Shih, Sophy T. F.
Carter, Rob
Versace, Vincent L.
McNamara, Kevin
author_facet Krass, Ines
Twigg, Michael J.
Mitchell, Bernadette
Wilson, Frances
Mohebbi, Mohammadreza
Trinder, Peta
Shih, Sophy T. F.
Carter, Rob
Versace, Vincent L.
McNamara, Kevin
author_sort Krass, Ines
collection PubMed
description BACKGROUND: The Pharmacy Diabetes Screening Trial (PDST) evaluated three approaches to screening for undiagnosed type 2 diabetes mellitus (T2DM) in community pharmacy: (1) paper-based risk assessment (AUSDRISK) alone; and AUSDRISK followed by a point of care test if AUSDRISK ≥ 12; with either (2) HbA1c; or (3) small capillary blood glucose Test (scBGT). This paper reports the perspectives and experiences of the pharmacy screening service of two key stakeholder groups: screening participants and general practitioners (GPs). METHODS: All referred participants (n = 2242) received an online survey to determine the outcome of the referral, as well as their level of satisfaction with the service. In addition, a random sample of 2,989 (20%) of non-referred participants were surveyed to determine their overall experience and level of satisfaction with the service. GPs to whom participants were referred were contacted to establish if, since the date of the screening service, their patient had (1) been to see them; (2) had further tests performed (FBG, RBG, OGTT, HbA1c); or (3) been diagnosed with diabetes or prediabetes. Descriptive statistics were reported for quantitative data. Factors associated with visiting the GP following screening were assessed using multivariable logistic regression. Qualitative data were analysed using content analysis. RESULTS: Response rates 16% (n = 369) and 17% (n = 520) were achieved for the three-month referred and non-referred participant surveys, respectively. Over 90% of respondents were very positive about the screening service (n = 784/853) and would recommend it to a family member or friend (n = 784/853). Participants also reported making significant improvements in diet and exercise, because of the screening. Among referred respondents, those who received a POC test were twice as likely to visit their GP compared to those who received a risk assessment only (OR 2.11 95% CI 1.46–3.06). GPs (15.8% response rate, n = 57/361) indicated that the referral worked well and that recommendations for follow-up care by the pharmacist were appropriate. CONCLUSION: Opportunistic screening of individuals during routine encounters with the community pharmacy in a previously undiagnosed population has been shown to foster positive engagement with consumers and GPs, which may assist in reducing the burden of T2DM on the individual and the community. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12913-023-10269-1.
format Online
Article
Text
id pubmed-10693079
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-106930792023-12-03 Participant and GP perspectives and experiences of screening for undiagnosed type 2 diabetes in community pharmacy during the Pharmacy Diabetes Screening Trial Krass, Ines Twigg, Michael J. Mitchell, Bernadette Wilson, Frances Mohebbi, Mohammadreza Trinder, Peta Shih, Sophy T. F. Carter, Rob Versace, Vincent L. McNamara, Kevin BMC Health Serv Res Research BACKGROUND: The Pharmacy Diabetes Screening Trial (PDST) evaluated three approaches to screening for undiagnosed type 2 diabetes mellitus (T2DM) in community pharmacy: (1) paper-based risk assessment (AUSDRISK) alone; and AUSDRISK followed by a point of care test if AUSDRISK ≥ 12; with either (2) HbA1c; or (3) small capillary blood glucose Test (scBGT). This paper reports the perspectives and experiences of the pharmacy screening service of two key stakeholder groups: screening participants and general practitioners (GPs). METHODS: All referred participants (n = 2242) received an online survey to determine the outcome of the referral, as well as their level of satisfaction with the service. In addition, a random sample of 2,989 (20%) of non-referred participants were surveyed to determine their overall experience and level of satisfaction with the service. GPs to whom participants were referred were contacted to establish if, since the date of the screening service, their patient had (1) been to see them; (2) had further tests performed (FBG, RBG, OGTT, HbA1c); or (3) been diagnosed with diabetes or prediabetes. Descriptive statistics were reported for quantitative data. Factors associated with visiting the GP following screening were assessed using multivariable logistic regression. Qualitative data were analysed using content analysis. RESULTS: Response rates 16% (n = 369) and 17% (n = 520) were achieved for the three-month referred and non-referred participant surveys, respectively. Over 90% of respondents were very positive about the screening service (n = 784/853) and would recommend it to a family member or friend (n = 784/853). Participants also reported making significant improvements in diet and exercise, because of the screening. Among referred respondents, those who received a POC test were twice as likely to visit their GP compared to those who received a risk assessment only (OR 2.11 95% CI 1.46–3.06). GPs (15.8% response rate, n = 57/361) indicated that the referral worked well and that recommendations for follow-up care by the pharmacist were appropriate. CONCLUSION: Opportunistic screening of individuals during routine encounters with the community pharmacy in a previously undiagnosed population has been shown to foster positive engagement with consumers and GPs, which may assist in reducing the burden of T2DM on the individual and the community. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12913-023-10269-1. BioMed Central 2023-12-01 /pmc/articles/PMC10693079/ /pubmed/38041094 http://dx.doi.org/10.1186/s12913-023-10269-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Krass, Ines
Twigg, Michael J.
Mitchell, Bernadette
Wilson, Frances
Mohebbi, Mohammadreza
Trinder, Peta
Shih, Sophy T. F.
Carter, Rob
Versace, Vincent L.
McNamara, Kevin
Participant and GP perspectives and experiences of screening for undiagnosed type 2 diabetes in community pharmacy during the Pharmacy Diabetes Screening Trial
title Participant and GP perspectives and experiences of screening for undiagnosed type 2 diabetes in community pharmacy during the Pharmacy Diabetes Screening Trial
title_full Participant and GP perspectives and experiences of screening for undiagnosed type 2 diabetes in community pharmacy during the Pharmacy Diabetes Screening Trial
title_fullStr Participant and GP perspectives and experiences of screening for undiagnosed type 2 diabetes in community pharmacy during the Pharmacy Diabetes Screening Trial
title_full_unstemmed Participant and GP perspectives and experiences of screening for undiagnosed type 2 diabetes in community pharmacy during the Pharmacy Diabetes Screening Trial
title_short Participant and GP perspectives and experiences of screening for undiagnosed type 2 diabetes in community pharmacy during the Pharmacy Diabetes Screening Trial
title_sort participant and gp perspectives and experiences of screening for undiagnosed type 2 diabetes in community pharmacy during the pharmacy diabetes screening trial
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10693079/
https://www.ncbi.nlm.nih.gov/pubmed/38041094
http://dx.doi.org/10.1186/s12913-023-10269-1
work_keys_str_mv AT krassines participantandgpperspectivesandexperiencesofscreeningforundiagnosedtype2diabetesincommunitypharmacyduringthepharmacydiabetesscreeningtrial
AT twiggmichaelj participantandgpperspectivesandexperiencesofscreeningforundiagnosedtype2diabetesincommunitypharmacyduringthepharmacydiabetesscreeningtrial
AT mitchellbernadette participantandgpperspectivesandexperiencesofscreeningforundiagnosedtype2diabetesincommunitypharmacyduringthepharmacydiabetesscreeningtrial
AT wilsonfrances participantandgpperspectivesandexperiencesofscreeningforundiagnosedtype2diabetesincommunitypharmacyduringthepharmacydiabetesscreeningtrial
AT mohebbimohammadreza participantandgpperspectivesandexperiencesofscreeningforundiagnosedtype2diabetesincommunitypharmacyduringthepharmacydiabetesscreeningtrial
AT trinderpeta participantandgpperspectivesandexperiencesofscreeningforundiagnosedtype2diabetesincommunitypharmacyduringthepharmacydiabetesscreeningtrial
AT shihsophytf participantandgpperspectivesandexperiencesofscreeningforundiagnosedtype2diabetesincommunitypharmacyduringthepharmacydiabetesscreeningtrial
AT carterrob participantandgpperspectivesandexperiencesofscreeningforundiagnosedtype2diabetesincommunitypharmacyduringthepharmacydiabetesscreeningtrial
AT versacevincentl participantandgpperspectivesandexperiencesofscreeningforundiagnosedtype2diabetesincommunitypharmacyduringthepharmacydiabetesscreeningtrial
AT mcnamarakevin participantandgpperspectivesandexperiencesofscreeningforundiagnosedtype2diabetesincommunitypharmacyduringthepharmacydiabetesscreeningtrial